Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.84
(-1.56%)
SEK 8.84
(-1.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 65.97 Million SEK | 25.22% |
| 2022 | 57.84 Million SEK | 3.96% |
| 2021 | 55.69 Million SEK | 337.1% |
| 2020 | 16.97 Million SEK | -130.84% |
| 2019 | 92.97 Million SEK | 17.37% |
| 2018 | 64.9 Million SEK | -1.55% |
| 2017 | 66.58 Million SEK | 18.33% |
| 2016 | 57.72 Million SEK | 118.0% |
| 2015 | 26.65 Million SEK | -24.8% |
| 2014 | 30.8 Million SEK | 143.2% |
| 2013 | -79.21 Million SEK | -427.7% |
| 2012 | 23.86 Million SEK | 24.63% |
| 2011 | 21.26 Million SEK | -7.04% |
| 2010 | 20.71 Million SEK | 6608.35% |
| 2009 | 5.74 Million SEK | -91.48% |
| 2008 | -1.7 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 25.8 Million SEK | 10.38% |
| 2024 Q3 | -278.5 Million SEK | -13071.43% |
| 2024 Q2 | 7.7 Million SEK | -91.03% |
| 2023 Q3 | 8.8 Million SEK | 0.0% |
| 2023 Q4 | 19.8 Million SEK | 125.0% |
| 2023 FY | - SEK | 25.22% |
| 2023 Q1 | 12.6 Million SEK | 16.99% |
| 2023 Q2 | 8.8 Million SEK | -30.16% |
| 2022 Q1 | 10.5 Million SEK | -8.02% |
| 2022 Q3 | 5.2 Million SEK | -18.75% |
| 2022 FY | - SEK | 3.96% |
| 2022 Q4 | 10.77 Million SEK | 107.12% |
| 2022 Q2 | 6.4 Million SEK | -39.05% |
| 2021 Q3 | 13.3 Million SEK | 315.63% |
| 2021 Q2 | 3.2 Million SEK | -54.29% |
| 2021 Q4 | 11.41 Million SEK | -14.17% |
| 2021 FY | - SEK | 337.1% |
| 2021 Q1 | 7 Million SEK | 116.97% |
| 2020 Q4 | -41.25 Million SEK | -271.9% |
| 2020 Q1 | 11.7 Million SEK | 4.44% |
| 2020 Q2 | -39.3 Million SEK | -435.9% |
| 2020 FY | - SEK | -130.84% |
| 2020 Q3 | 24 Million SEK | 161.07% |
| 2019 Q3 | 28.4 Million SEK | 951.85% |
| 2019 Q4 | 11.2 Million SEK | -60.55% |
| 2019 Q1 | 12.6 Million SEK | 226.17% |
| 2019 FY | - SEK | 17.37% |
| 2019 Q2 | 2.7 Million SEK | -78.57% |
| 2018 Q4 | 3.86 Million SEK | -70.95% |
| 2018 FY | - SEK | -1.55% |
| 2018 Q3 | 13.3 Million SEK | -33.5% |
| 2018 Q2 | 20 Million SEK | 3.63% |
| 2018 Q1 | 19.3 Million SEK | 46.15% |
| 2017 Q2 | 200 Thousand SEK | -98.31% |
| 2017 Q1 | 11.8 Million SEK | 596.17% |
| 2017 Q3 | 28.5 Million SEK | 14150.0% |
| 2017 Q4 | 13.2 Million SEK | -53.66% |
| 2017 FY | - SEK | 18.33% |
| 2016 Q2 | 13.1 Million SEK | 59.76% |
| 2016 Q3 | 24.7 Million SEK | 88.55% |
| 2016 Q4 | 1.69 Million SEK | -93.14% |
| 2016 Q1 | 8.2 Million SEK | 813.14% |
| 2016 FY | - SEK | 118.0% |
| 2015 Q3 | 9 Million SEK | 181.25% |
| 2015 Q1 | 8.8 Million SEK | 23.44% |
| 2015 Q4 | 898 Thousand SEK | -90.02% |
| 2015 Q2 | 3.2 Million SEK | -63.64% |
| 2015 FY | - SEK | -24.8% |
| 2014 Q2 | 3.6 Million SEK | -38.98% |
| 2014 Q4 | 7.12 Million SEK | -27.26% |
| 2014 FY | - SEK | 143.2% |
| 2014 Q1 | 5.9 Million SEK | 66.71% |
| 2014 Q3 | 9.8 Million SEK | 172.22% |
| 2013 FY | - SEK | -427.7% |
| 2013 Q2 | 5.69 Million SEK | 4457.6% |
| 2013 Q4 | 3.53 Million SEK | 103.85% |
| 2013 Q3 | -92.01 Million SEK | -1715.18% |
| 2013 Q1 | 125 Thousand SEK | -98.03% |
| 2012 Q2 | 8.29 Million SEK | 87.39% |
| 2012 Q4 | 6.35 Million SEK | 314.41% |
| 2012 Q1 | 4.42 Million SEK | -20.62% |
| 2012 FY | - SEK | 24.63% |
| 2012 Q3 | 1.53 Million SEK | -81.5% |
| 2011 Q4 | 5.57 Million SEK | -2.82% |
| 2011 Q2 | 1.58 Million SEK | -73.41% |
| 2011 Q1 | 5.97 Million SEK | 57.37% |
| 2011 FY | - SEK | -7.04% |
| 2011 Q3 | 5.73 Million SEK | 261.11% |
| 2010 Q4 | 3.79 Million SEK | 111.35% |
| 2010 FY | - SEK | 6608.35% |
| 2010 Q1 | 4.71 Million SEK | 0.0% |
| 2010 Q3 | 1.79 Million SEK | -82.18% |
| 2010 Q2 | 10.08 Million SEK | 113.87% |
| 2009 FY | - SEK | -91.48% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 185.551% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 83.982% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 83.982% |
| Arcoma AB | 6.24 Million SEK | -956.002% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 173.325% |
| BICO Group AB (publ) | 322.3 Million SEK | 79.529% |
| CellaVision AB (publ) | 207.24 Million SEK | 68.164% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 196.452% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 336.12% |
| C-Rad AB (publ) | 48.9 Million SEK | -34.915% |
| Duearity AB (publ) | -24.77 Million SEK | 366.27% |
| Dignitana AB (publ) | -264 Thousand SEK | 25092.045% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 175.233% |
| Getinge AB (publ) | 5.92 Billion SEK | 98.887% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 198.11% |
| Iconovo AB (publ) | -35.33 Million SEK | 286.722% |
| Integrum AB (publ) | 8.76 Million SEK | -653.053% |
| Luxbright AB (publ) | -23.86 Million SEK | 376.448% |
| Mentice AB (publ) | 28.87 Million SEK | -128.515% |
| OssDsign AB (publ) | -122.02 Million SEK | 154.072% |
| Paxman AB (publ) | 31.22 Million SEK | -111.275% |
| Promimic AB (publ) | -3.68 Million SEK | 1890.961% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 143.838% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 227.301% |
| ScandiDos AB (publ) | -13.35 Million SEK | 594.003% |
| Sectra AB (publ) | 615.06 Million SEK | 89.273% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 227.683% |
| Senzime AB (publ) | -118.82 Million SEK | 155.527% |
| SpectraCure AB (publ) | -20.96 Million SEK | 414.65% |
| Stille AB | 56.04 Million SEK | -17.733% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 102.072% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 47.873% |